- Vertex's Crinetics deal points to big ambitions for cystic fibrosis leaderVertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech s…Endpoints · 17d ago↗ source
- Tampa General kicks off legal fight over Lilly's 340B restrictionsTampa General Hospital sued Eli Lilly for halting its 340B discounts, kicking off a broader fight over whether pharmaceutical companies can condition drug discounts on new claims data requirements.…Endpoints · 17d ago↗ source
- Vera's IgAN approval kicks off competition with OtsukaVera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobu…